A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma

Trial Profile

A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Dec 2014

At a glance

  • Drugs Aldesleukin (Primary) ; Melanoma vaccine gp100
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Oct 2011 Actual end date May 2011 added as reported by ClinicalTrials.gov.
    • 11 Oct 2011 Actual end date May 2011 added as reported by ClinicalTrials.gov.
    • 11 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top